Streetbeat News

SCTL

Societal CDMO Inc

Employees

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

recro gainesville, llc, provides solid dosage form development, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. specializing in extended release solid dose and dea controlled substances, recro has the experts to deliver clients’ most complex pharmaceutical development and manufacturing projects in its best-in-class, 97,000-square-foot manufacturing facility. for more information about recro’s flexible cdmo solutions, visit www.recrogainesville.com

Open

1.09

Mkt cap

116M

Volume

513K

High

1.10

P/E Ratio

-7.86

52-wk high

1.28

Low

1.09

Div yield

N/A

52-wk low

0.26

U.S. stocks showed mixed performance with the S&P 500 rising by 0.3%. Hayward Holdings (HAYW) shares surged over 17% following better-than-expected Q4 results. Societal CDMO (SCTL) and Enveric Biosciences (ENVB) also saw significant gains, while LivePerson (LPSN), Endava (DAVA), and Kineta (KA) experienced sharp declines. The market saw varied sector performance, with real estate leading and health care lagging.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 7:31 pm

Butterfly Network, Inc. (BFLY) shares fell by 22% after reporting a larger-than-expected GAAP loss for Q4, despite beating sales estimates. Other stocks experienced significant movements, with Enveric Biosciences, Inc. (ENVB) and Societal CDMO, Inc. (SCTL) among the top gainers, while J-Long Group Limited (JL) and Golden Minerals Company (AUMN) led the losers.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 7:00 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Societal CDMO and Enveric Biosciences saw substantial gains, while Kineta and Ironwood Pharmaceuticals faced notable declines. Revance Therapeutics and Castle Biosciences reported their Q4 earnings, influencing their stock performance.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:32 pm

Societal CDMO's stock price has increased following the announcement of its acquisition by CoreRx. The definitive agreement marks a significant move for both companies in the pharmaceutical manufacturing sector.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 5:27 pm

U.S. stocks traded mixed with the Nasdaq Composite up by 100 points. Best Buy reported better-than-expected Q4 earnings, beating estimates with an EPS of $2.72 and sales of $14.646 billion. The company also increased its quarterly dividend by 2% and provided FY25 guidance. Societal CDMO, Enveric Biosciences, and Vertex saw significant stock price increases, while LivePerson, Endava, and Kineta experienced notable declines. Oil and gold prices rose, and economic indicators showed mixed results globally.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 5:24 pm

U.S. stocks showed mixed performance with the Nasdaq gaining 100 points following the release of PCE data indicating a slight ease in inflation from 2.6% to 2.4%. Societal CDMO, Enveric Biosciences, and Volcon saw significant stock increases due to acquisition and licensing news, while LivePerson, The Chemours Company, and Ironwood Pharmaceuticals experienced sharp declines due to disappointing financial results and trial outcomes.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 3:40 pm

Societal CDMO Inc (NASDAQ:SCTL) is trading higher after the announcement that CoreRx Inc. will acquire all outstanding shares for $1.10 per share in cash. The transaction, expected to close early in Q2 2024, is seen as delivering substantial value to shareholders despite some long-term investor dissatisfaction with the takeover price. SCTL shares surged 132.6% to $1.07.

Portfolio Pulse from Vandana Singh

February 29, 2024 | 2:54 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Enveric Biosciences, Societal CDMO, and NeuroBo Pharmaceuticals were among the top gainers, with Enveric Biosciences leading at a 162.3% increase. On the losing side, Ironwood Pharmaceuticals, Milestone Pharmaceuticals, and Butterfly Network saw notable declines, with Ironwood Pharmaceuticals dropping by 27.7%. Earnings releases influenced some of the stock movements.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:07 pm

Okta, Inc. (NASDAQ:OKTA) shares surged in pre-market trading by around 24% after reporting Q4 earnings and sales that exceeded analyst expectations, alongside strong guidance. Other stocks also showed significant pre-market movements, with notable gainers including Volcon, Inc. (NASDAQ:VLCN), Societal CDMO, Inc. (NASDAQ:SCTL), and Duolingo, Inc. (NASDAQ:DUOL) due to various positive developments. Conversely, Snowflake Inc. (NYSE:SNOW) and WW International, Inc. (NASDAQ:WW) were among the prominent losers, with Snowflake's CEO retiring and WW International reporting disappointing Q4 results.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 1:04 pm

RBC Capital analyst Sean Dodge downgraded Societal CDMO (NASDAQ:SCTL) from Outperform to Sector Perform and reduced the price target from $1.25 to $1.1.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.